August Troendle Sells 27,174 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 27,174 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $618.79, for a total value of $16,814,999.46. Following the completion of the transaction, the chief executive officer directly owned 561,195 shares of the company’s stock, valued at $347,261,854.05. This trade represents a 4.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Medpace Stock Up 1.3%

MEDP traded up $8.11 on Friday, reaching $620.75. The company had a trading volume of 225,439 shares, compared to its average volume of 347,887. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The stock has a market capitalization of $17.33 billion, a PE ratio of 36.39, a P/E/G ratio of 2.71 and a beta of 1.15. The stock has a 50-day moving average price of $547.09 and a 200-day moving average price of $491.80.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in MEDP. BlackRock Inc. acquired a new stake in shares of Medpace in the second quarter valued at about $1,323,047,000. AQR Capital Management LLC boosted its holdings in Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares in the last quarter. Madison Asset Management LLC acquired a new position in Medpace during the second quarter worth about $128,956,000. Bank of America Corp DE purchased a new position in Medpace in the second quarter valued at about $116,891,000. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after acquiring an additional 211,411 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and increased their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Leerink Partners set a $620.00 price objective on Medpace in a research note on Thursday, July 23rd. Barclays set a $600.00 price objective on Medpace in a research report on Thursday, July 23rd. Finally, Royal Bank Of Canada boosted their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.